

ASX Announcement

AdAlta SPP completion, bringing funds raised to \$4.73 million

MELBOURNE Australia, 15th August 2018, AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to advise the result of the Company's Share Purchase Plan (SPP) announced to the ASX on 16 July 2018 having closed on 10 August 2018. The Company received and accepted applications totaling \$477,603.30 which will result in the issue of 1,592,011 shares, taking total funds raised when combined with the recent Placement, to \$4.73 million.

SPP and Placement raise total of \$4.73 million to advance AD-214

The combined SPP and Placement will fund manufacturing and pre-clinical studies of AD-214, internal research and development of new i-bodies and associated corporate costs.

Commenting on the close of the SPP, AdAlta CEO, Sam Cobb commented, "We are heartened by the level of support seen from our existing shareholders through this Share Purchase Plan process. Combined with our recent Placement to institutional and sophisticated investors, the SPP has brought our funds raised to \$4.73 million."

"We have a big few months coming up as we move AD-214, our next generation antibody therapeutics for Idiopathic Pulmonary Fibrosis, into manufacturing and look forward to keeping investors across our progress."

The Company expects the holder statements to be dispatched to shareholders on the 16th August 2018.

-ENDS-

Notes to Editors

About AdAlta

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au.

For more information, please contact:

AdAlta Limited

Sam Cobb, CEO

Tel: +61 (0)3 9479 5159

E: s.cobb@adalta.com.au